Erasca stock sinks almost 50% after patient death in cancer drug trial

Erasca shares sank 50% after a patient death in a drug trial, a severe setback that raises immediate safety concerns and likely pressures the program's outlook. The move is highly material for the stock and may also weigh on broader biotech sentiment, though the impact is company-specific rather than market-wide.

Analysis

Erasca shares sank 50% after a patient death in a drug trial, a severe setback that raises immediate safety concerns and likely pressures the program's outlook. The move is highly material for the stock and may also weigh on broader biotech sentiment, though the impact is company-specific rather than market-wide.